CryoLife seeks partner for FibRX:
This article was originally published in Clinica
CryoLife is now free to discuss partnerships and license agreements for its fibrin-based bioadhesive, FibRX. In March, Bayer paid CryoLife $250,000 for exclusive rights to negotiate a licence, but no agreement was made (see Clinica No 699, p 13). CryoLife, which is based in Atlanta, Georgia, plans to apply for FDA approval to begin human trials for FibRX in the second quarter of 1997.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.